Ablukast

Ablukast
Clinical data
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]chroman-2-carboxylic acid;
CAS Number	96566-25-5;
PubChem CID	57109;
ChemSpider	51496 ;
UNII	000TKM5BBQ;
KEGG	D02739 ;
ChEMBL	ChEMBL22016 ;
CompTox Dashboard (EPA)	DTXSID20869277 ;
Chemical and physical data
Formula	C28H34O8
Molar mass	498.572 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCC1=C(C=CC(=C1O)C(=O)C)OCCCCCOC2=CC3=C(CCC(O3)C(=O)O)C=C2C(=O)C;
	InChI InChI=1S/C28H34O8/c1-4-8-21-23(12-10-20(17(2)29)27(21)31)34-13-6-5-7-14-35-26-16-25-19(15-22(26)18(3)30)9-11-24(36-25)28(32)33/h10,12,15-16,24,31H,4-9,11,13-14H2,1-3H3,(H,32,33) ; Key:FGGYJWZYDAROFF-UHFFFAOYSA-N ;
	(verify)

Ablukast (INN) is an experimental drug that is a leukotriene antagonist. It was investigated for potential applications in the treatment of inflammatory conditions, including asthma, skin disorders, and inflammatory bowel disease.^[1]^[2] It reached Phase III clinical trials, but development was discontinued in 1996.^[2]

References

^ Rosenbach T, Csatò M, Czarnetzki BM (January 1988). "Studies on the role of leukotrienes in murine allergic and irritant contact dermatitis". The British Journal of Dermatology. 118 (1): 1–6. doi:10.1111/j.1365-2133.1988.tb01743.x. PMID 2829957. S2CID 1164113.
^ ^a ^b "Ablukast". Adis Insight.

External links

Media related to Ablukast at Wikimedia Commons

[1] Rosenbach T, Csatò M, Czarnetzki BM (January 1988). "Studies on the role of leukotrienes in murine allergic and irritant contact dermatitis". The British Journal of Dermatology. 118 (1): 1–6. doi:10.1111/j.1365-2133.1988.tb01743.x. PMID 2829957. S2CID 1164113.

[adisinsight-2] "Ablukast". Adis Insight.

[1]

[2]